{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:09:22Z","timestamp":1793866162219,"version":"4.6.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hereditary angioedema (HAE) is a rare, unpredictable disease that imposes a substantial and multifaceted burden on patients\u2019 daily lives, with many not achieving the World Allergy Organization (WAO)\/European Academy of Allergy and Clinical Immunology (EAACI) recommended treatment goal of normalisation of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In March 2025, a European expert committee convened to discuss how to effectively implement WAO\/EAACI guidelines in clinical practice, identifying a Treat-to-Target (T2T) approach to support consistent adoption of guideline recommendations into routine care. Through iterative expert discussion and consensus, a T2T algorithm was developed to support the achievement of optimal treatment goals for adolescents and adults with HAE, providing a structured, patient-centred strategy to guide HAE management. Feasibility and clarity of the consensus T2T algorithm were evaluated via an online survey of 64 European clinicians and 15 representatives from patient organisations. Feedback from the survey was used to refine the final version.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The T2T algorithm provides a visual, practical framework that offers guidance on initiating long-term prophylaxis (LTP), as well as setting and assessing individualised short- and long-term targets and treatment plans. Target attainment is achieved through regular monitoring, involving a comprehensive assessment of disease activity and burden, analysis of the causes of breakthrough attacks, and considering optimising management or switching LTP treatment when targets are not being reached. The ultimate goal of treatment for HAE is to achieve normalisation of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By setting clear, measurable, and individualised treatment targets supported by shared decision-making, regular monitoring and treatment optimisation as needed, this consensus-derived T2T algorithm aims to promote more consistent care within the HAE community and ultimately improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1773279","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:10:32Z","timestamp":1770894632000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee"],"prefix":"10.3389","volume":"17","author":[{"given":"Mauro","family":"Cancian","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University Hospital of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Caballero","sequence":"additional","affiliation":[{"name":"Department of Allergy, Hospital Universitario La Paz, Hospital La Paz Health Research Institute (IdiPAZ), Center for Biomedical Network Research on Rare Diseases (CIBERER) (U754)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boccon-Gibod","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Reference Center for Angioedema (CREAK), Grenoble Alpes University Hospital (CHUGA)","place":["Grenoble, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Buttgereit","sequence":"additional","affiliation":[{"name":"Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology, Charit\u00e9-Universit\u00e4tsmedizin","place":["Berlin, Germany"]},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Immunology and Allergology","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Cohn","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Center (UMC), University of Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrem","family":"Eren","sequence":"additional","affiliation":[{"name":"Department of Immunology, University Hospital Southampton National Health Service (NHS) Foundation Trust","place":["Southampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorena","family":"Kiani-Alikhan","sequence":"additional","affiliation":[{"name":"Department of Immunology, Royal Free London National Health Service Foundation Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, National Reference Centre for Angioedema (CREAK), Centre Hospitalier Universitaire de Lille (CHU) Lille, University of Lille, French National Institute for Health Research (INSERM), Institute for Translational Research in Inflammation U1286","place":["Lille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mandelin","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Helsinki University and Helsinki University Central Hospital","place":["Helsinki, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zanichelli","sequence":"additional","affiliation":[{"name":"Operative Unit of Medicine, Angioedema Center, IRCCS Policlinico San Donato","place":["Milan, Italy"]},{"name":"Department of Biomedical Sciences for Health, University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Farkas","sequence":"additional","affiliation":[{"name":"Hungarian Angioedema Center of Reference and Excellence, Department of Internal, Medicine and Haematology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-024-03265-z","article-title":"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review","volume":"19","author":"Guan","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/3028617","article-title":"The disease burden of hereditary angioedema: insights from a survey in french-canadians from quebec","volume":"2024","author":"Boursiquot","year":"2024","journal-title":"J Immunol Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2025.101100","article-title":"Real-world treatment patterns and burden-of-disease of sub-optimally controlled hereditary angioedema","volume":"18","author":"Farkas","year":"2025","journal-title":"World Allergy Organ J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s13023-025-03739-8","article-title":"Unmet needs in hereditary angioedema: an international survey of physicians","volume":"20","author":"Buttgereit","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2500\/aap.2025.46.250048","article-title":"Quality of life and burden of disease in patients with hereditary angioedema and their caregivers","volume":"46","author":"Levy","year":"2025","journal-title":"Allergy Asthma Proc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08897-8","article-title":"The mortality from hereditary angioedema worldwide: a review of the real-world data literature","volume":"62","author":"Minafra","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.05.055","article-title":"Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency","volume":"130","author":"Bork","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","article-title":"The international\/canadian hereditary angioedema guideline","volume":"15","author":"Betschel","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-021-01717-4","article-title":"Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey","volume":"16","author":"Mendivil","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.jaip.2023.03.032","article-title":"The disease burden and societal costs of hereditary angioedema","volume":"11","author":"Fijen","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0329585","DOI":"10.1371\/journal.pone.0329585","article-title":"Barriers and promoters to adapting research findings to clinical care in hereditary angioedema in the United States: A qualitative study","volume":"20","author":"Langmack","year":"2025","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","article-title":"Hereditary angioedema: Epidemiology and burden of disease","volume":"41","author":"Lumry","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2010.31.3394","article-title":"The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression","volume":"31","author":"Lumry","year":"2010","journal-title":"Allergy Asthma Proc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2021.42.210029","article-title":"Caregivers\u2019 role in managing hereditary angioedema and perceptions of treatment-related burden","volume":"42","author":"Craig","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100792","article-title":"The multifactorial impact of receiving a hereditary angioedema diagnosis","volume":"16","author":"Raasch","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2023.1143897","article-title":"Hereditary angioedema (HAE) in Belgium: results from a national survey","volume":"4","author":"Van der Poorten","year":"2023","journal-title":"Front Allergy"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2014","article-title":"Burden of illness in hereditary angioedema: A conceptual model","volume":"95","author":"Bygum","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.12.1079","article-title":"Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelines","volume":"155","author":"Cohn","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B20","unstructured":"KalVista Pharmaceuticals receives positive CHMP Opinion for sebetralstat for the treatment of hereditary angioedema attacks\n          \n          2025"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/all.16643","article-title":"Delays and barriers related to the treatment of hereditary angioedema attacks in Italy","volume":"80","author":"Cancian","year":"2025","journal-title":"Allergy"},{"key":"B22","unstructured":"European Commission approves CSL\u2019s ANDEMBRY\n          \n          2025"},{"key":"B23","unstructured":"U.S. Food and Drug Administration Approves CSL\u2019s ANDEMBRY\n          \n          2025"},{"key":"B24","unstructured":"DAWNZERA\u2122 (donidalorsen) approved in the European Union for hereditary angioedema (HAE)\n          \n          2026"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2025.2509782","article-title":"Hereditary angioedema treatment beyond biologics: current state of preventive and on-demand approaches and new perspectives","volume":"26","author":"Zanichelli","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e50507","DOI":"10.7759\/cureus.50507","article-title":"Implementation of the treat-to-target approach in psoriatic arthritis and its outcomes in routine clinical practice","volume":"15","author":"Din","year":"2023","journal-title":"Cureus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.129106","article-title":"Treat-to-target trials in diabetes","volume":"18","author":"Wangnoo","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.S284029","article-title":"Optimal management of hereditary angioedema: shared decision-making","volume":"14","author":"Banerji","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1109283","article-title":"Shared decision making--pinnacle of patient-centered care","volume":"366","author":"Barry","year":"2012","journal-title":"N Engl J Med"},{"key":"B34","unstructured":"The power of partnership: Shared decision making in HAE\n          \n          2024"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e12295","DOI":"10.1002\/clt2.12295","article-title":"Sensitivity to change and minimal clinically important difference of the angioedema control test","volume":"13","author":"Fijen","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/pharmaceutics13071100","article-title":"Factors contributing to medication adherence in patients with a chronic condition: A scoping review of qualitative research","volume":"13","author":"Kvarnstr\u00f6m","year":"2021","journal-title":"Pharmaceutics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12875-019-1019-3","article-title":"Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study","volume":"20","author":"Fernandez-Lazaro","year":"2019","journal-title":"BMC Fam Pract"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.33590\/emjallergyimmunol\/IEYW6199","article-title":"Effectiveness of berotralstat\u25bc for hereditary angioedema prophylaxis","volume":"10","author":"Boccon-Gibod","year":"2025","journal-title":"EMJ Allergy Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5114\/ada.2024.144488","article-title":"Attack frequency and associated factors in hereditary angioedema patients: a single-centre experience","volume":"42","author":"Durmaz","year":"2025","journal-title":"Postepy Dermatol Alergol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ajog.2008.04.034","article-title":"Disease expression in women with hereditary angioedema","volume":"199","author":"Bouillet","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.5414\/alx02523e","article-title":"Dietary and physical trigger factors in hereditary angioedema: Self-conducted investigation and literature overview","volume":"8","author":"Zarnowski","year":"2024","journal-title":"Allergol Select"},{"key":"B42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/medicina61010153","article-title":"Enhancing therapy adherence: impact on clinical outcomes, healthcare costs, and patient quality of life","volume":"61","author":"Religioni","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.anai.2024.08.106","article-title":"Drug patterns, clinical outcomes, and economic costs among hereditary angioedema patients initiating long-term prophylaxis","volume":"133","author":"Kutrieb","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13223-025-00969-0","article-title":"Factors contributing to non-compliance with on-demand treatment guidelines in hereditary angioedema","volume":"21","author":"Betschel","year":"2025","journal-title":"Allergy Asthma Clin Immunol."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2017.050","article-title":"Encouraging adherence to long-term medication","volume":"40","author":"Usherwood","year":"2017","journal-title":"Aust Prescr"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/skinhd\/vzaf055","article-title":"Observations on quality of life and disease control in patients with hereditary angioedema","volume":"5","author":"Buttgereit","year":"2025","journal-title":"Skin Health Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.290424.eci","article-title":"Evolving concepts in treat-to-target strategies for systemic lupus erythematosus","volume":"35","author":"Nikolopoulos","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2025.501135","article-title":"Precision medicine and Treat-to-Target approach in atopic dermatitis: enhancing personalized care and outcomes","volume":"100","author":"Hartmann","year":"2025","journal-title":"Bras Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.05.012","article-title":"Treat-to-target\u201d: A call for earlier targeted intervention in asthma","volume":"13","author":"Couillard","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.0000000000000249","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"82","author":"Jones","year":"2025","journal-title":"Hypertension"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e16526","DOI":"10.1111\/ene.16526","article-title":"Treating to target in multiple sclerosis: Do we know how to measure whether we hit it","volume":"31","author":"Bsteh","year":"2024","journal-title":"Eur J Neurol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216819","article-title":"Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)","volume":"79","author":"Ramiro","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"keaf142.213","DOI":"10.1093\/rheumatology\/keaf142.213","article-title":"P176\u2003Real-world treat-to-target strategy in psoriatic arthritis: 48 week results from the MONITOR-PsA cohort","volume":"64","author":"Letarouilly","year":"2025","journal-title":"Rheumatology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0390.PV215","article-title":"Treat-to-Target attainment in patients with SLE from the RHEUMA.PT SLE Registry: A multicenter Portuguese cross-sectional study of 795 patients","volume":"52","author":"Mendes","year":"2025","journal-title":"J Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0875","article-title":"Expert review and consensus on the treat-to-target management of hereditary angioedema: from scientific evidence to clinical practice","volume":"33","author":"Caballero","year":"2023","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1773279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:10:34Z","timestamp":1770894634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1773279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2026.1773279"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1773279","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1773279"}}